PH10383A - 4-phenylpiperidine compounds - Google Patents

4-phenylpiperidine compounds

Info

Publication number
PH10383A
PH10383A PH15445A PH15445A PH10383A PH 10383 A PH10383 A PH 10383A PH 15445 A PH15445 A PH 15445A PH 15445 A PH15445 A PH 15445A PH 10383 A PH10383 A PH 10383A
Authority
PH
Philippines
Prior art keywords
phenylpiperidine compounds
phenylpiperidine
compounds
Prior art date
Application number
PH15445A
Inventor
J Christensen
R Squires
Original Assignee
Ferrosan As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9778288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH10383(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrosan As filed Critical Ferrosan As
Publication of PH10383A publication Critical patent/PH10383A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH15445A 1973-01-30 1974-01-29 4-phenylpiperidine compounds PH10383A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB449673A GB1422263A (en) 1973-01-30 1973-01-30 4-phenyl-piperidine compounds

Publications (1)

Publication Number Publication Date
PH10383A true PH10383A (en) 1977-03-02

Family

ID=9778288

Family Applications (1)

Application Number Title Priority Date Filing Date
PH15445A PH10383A (en) 1973-01-30 1974-01-29 4-phenylpiperidine compounds

Country Status (20)

Country Link
US (2) US3912743A (en)
JP (2) JPS5946216B2 (en)
AT (1) AT333759B (en)
BE (1) BE810310A (en)
CA (1) CA1038390A (en)
CH (1) CH592059A5 (en)
DE (1) DE2404113C2 (en)
DK (1) DK149843C (en)
ES (2) ES422734A1 (en)
FI (1) FI57932C (en)
FR (1) FR2215233B1 (en)
GB (1) GB1422263A (en)
HK (1) HK13081A (en)
IE (1) IE38801B1 (en)
IT (1) IT1054157B (en)
LU (2) LU69264A1 (en)
NL (2) NL179187C (en)
NO (1) NO144568C (en)
PH (1) PH10383A (en)
SE (1) SE401827B (en)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800378A (en) * 1972-06-07 1974-04-02 Rca Corp Method of making a directly-heated cathode
US4442113A (en) * 1981-05-07 1984-04-10 A/S Ferrosan Long-term weight reduction of obese patients using femoxetine
US4485109A (en) * 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
DK149624C (en) * 1983-03-07 1987-02-02 Ferrosan As PROCEDURE FOR THE PREPARATION OF (+) - TRANS-3 - (((4-METHOXYPHENOXY) -METHYL) -1-METHYL-4-PHENYLPIPERIDINE OR A PHARMACEUTICAL ACCEPTABLE SALT FROM A MIXTURE OF ENANTIOMY
US4593036A (en) * 1984-02-07 1986-06-03 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]-1-methylpiperidine useful as 5-HT potentiator
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
DE3680184D1 (en) * 1985-08-10 1991-08-14 Beecham Group Plc METHOD FOR PRODUCING ARYLPIPERIDINE CARBINOL.
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
NO158038C (en) * 1985-10-21 1988-06-29 Standard Tel Kabelfab As CABLE.
ES2058061T3 (en) * 1985-10-25 1994-11-01 Beecham Group Plc DERIVED FROM PIPERIDINE, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
US5017585A (en) * 1986-11-03 1991-05-21 Novo Nordisk A/S Method of treating calcium overload
DK231088D0 (en) * 1988-04-28 1988-04-28 Ferrosan As PIPERIDE CONNECTIONS, THEIR PREPARATION AND USE
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK588289D0 (en) * 1989-11-22 1989-11-22 Ferrosan As NEW HETEROCYCLIC CHEMISTRY
DK640289D0 (en) * 1989-12-18 1989-12-18 Ferrosan As NEW HETEROCYCLIC CHEMISTRY
IL98757A (en) * 1990-07-18 1997-01-10 Novo Nordisk As Piperidine derivatives their preparation and pharmaceutical compositions containing them
WO1992009281A2 (en) * 1990-11-24 1992-06-11 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
US5512584A (en) * 1991-04-16 1996-04-30 Basf Aktiengesellschaft 1,3,4-trisubstituted piperidine derivatives, the preparation and use thereof
DE4112353A1 (en) * 1991-04-16 1992-10-22 Basf Ag 1,3,4-TRISUBSTITUTED PIPERIDINE DERIVATIVES, THEIR PRODUCTION AND USE
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
GB9305175D0 (en) * 1993-03-13 1993-04-28 Smithkline Beecham Plc Novel process
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
EP0639568A1 (en) * 1993-08-19 1995-02-22 Novo Nordisk A/S Piperidine compounds, their preparation and use in the treatment of neurodegenerative disorders
US5446057A (en) * 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
ES2102295B1 (en) * 1994-03-18 1998-04-01 Ferrer Int NEW COMPOUNDS DERIVED FROM N-BENZOILMETIL-PIPERIDINA.
AR001982A1 (en) * 1995-02-06 1998-01-07 Smithkline Beecham Plc PAROXETINE CHLORHYDRATE ANHYDRATED, AND PROCEDURE FOR ITS PREPARATION
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
JPH11505229A (en) * 1995-05-17 1999-05-18 ノボ ノルディスク アクティーゼルスカブ Method for producing 4-aryl-piperidine derivatives
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
DE69607904T2 (en) * 1995-08-16 2000-10-05 Eli Lilly And Co., Indianapolis Potentiation of serotonin drug response
NZ315677A (en) * 1995-09-07 2000-02-28 F 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method
ES2121685B1 (en) * 1996-04-10 1999-09-16 Vita Invest Sa PROCEDURE FOR THE OBTAINING OF (+) - TRANS-4 (4-FLUORO-FENIL) -3-HIDROXIMETIL-1-METHYLPIPERIDINE.
JP3446468B2 (en) 1996-04-15 2003-09-16 旭硝子株式会社 Method for producing piperidine carbinols
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (en) * 1996-05-31 2007-02-14 旭硝子株式会社 Method for producing paroxetine
DE69739561D1 (en) 1996-06-13 2009-10-15 Sumitomo Chemical Co Piperidine derivatives as intermediates for the preparation of paroxetines and process for their preparation
HU221921B1 (en) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzyl-piperidine or tetrahydro-pyridine derivatives and processes for producing them
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
GB9623359D0 (en) * 1996-11-09 1997-01-08 Smithkline Beecham Plc Novel process
GB9700690D0 (en) * 1997-01-15 1997-03-05 Smithkline Beecham Plc Novel process
CA2284732C (en) * 1997-04-07 2008-06-17 Georgetown University Analogs of cocaine
GB9710004D0 (en) 1997-05-17 1997-07-09 Knoll Ag Chemical process
AP9901698A0 (en) 1997-05-29 1999-12-31 Smithkline Beecham Corp Novel process.
AU3108097A (en) 1997-06-10 1998-12-30 Synthon B.V. 4-phenylpiperidine compounds
CN1092654C (en) * 1997-06-10 2002-10-16 斯索恩有限公司 4-phenylpiperidine compound
CA2212451C (en) * 1997-08-07 2001-10-02 Brantford Chemicals Inc. Stereoselective and useful preparation of 3-substituted 4-aryl piperidine compounds
ES2137131B1 (en) * 1998-02-06 2000-09-16 Vita Invest Sa DERIVATIVE OF PIPERIDINONE PROCEDURE FOR OBTAINING AND PROCEDURE FOR ITS USE.
AU2847199A (en) * 1998-03-16 1999-10-11 Smithkline Beecham Plc Crystalline form of paroxetine
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
TR200002939T2 (en) * 1998-04-09 2001-02-21 Smithkline Beecham Plc Paroxetine maleate
GB9808896D0 (en) * 1998-04-25 1998-06-24 Smithkline Beecham Plc Novel compound
EP0969002B1 (en) 1998-06-29 2003-08-27 SUMIKA FINE CHEMICALS Co., Ltd. L-tartrate of trans-(-)-4-(4-fluorophenyl)-3-hydroxymethyl-piperidine compound and process for preparing the same
CH689805A8 (en) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing it.
ES2138937B1 (en) * 1998-07-07 2000-10-01 Medichem Sa PAROXETINE MALEATE POLYMORPH AND CONTAINING PHARMACEUTICAL FORMULATIONS.
IL141286A0 (en) * 1998-08-07 2002-03-10 Smithkline Beechmam Plc Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride
AU769260B2 (en) 1998-10-07 2004-01-22 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
PT1135383E (en) * 1998-11-30 2004-04-30 Smithkline Beecham Plc PARANXIN PROPAN-2-OL MIXED SOLVATES
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
AU2200400A (en) * 1998-12-22 2000-07-12 Pentech Pharmaceuticals, Inc. Process for preparing arylpiperidine carbinol intermediates and derivatives
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9915303D0 (en) * 1999-06-30 1999-09-01 Smithkline Beecham Plc Novel process
DK1109806T3 (en) * 1999-07-01 2003-12-22 Italfarmaco Spa Complexes of paroxetine with cyclodextrins or cyclodextrin derivatives
GB9915727D0 (en) * 1999-07-03 1999-09-08 Smithkline Beecham Plc Novel compound and process
GB9916187D0 (en) * 1999-07-09 1999-09-08 Smithkline Beecham Plc Novel process
GB9916392D0 (en) * 1999-07-13 1999-09-15 Smithkline Beecham Plc Novel process
IT1313702B1 (en) 1999-08-02 2002-09-09 Chemi Spa PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED DERIVATIVES OF 4-PHENYL-PIPERIDINS.
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
GB9920147D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel process
GB9923539D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9923540D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9924855D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel processes
WO2001029002A1 (en) * 1999-10-20 2001-04-26 Smithkline Beecham Plc Process for the preparation of 4-(fluorophenyl)piperidine esters
GB9924882D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel process
US6503927B1 (en) 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
CZ20023694A3 (en) 2000-05-12 2003-05-14 Synthon B. V. Tosylate salts of 4-(p-fluorophenyl)-piperidine-3-methanols
US6833458B2 (en) 2000-06-05 2004-12-21 Development Center For Biotechnology Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates
US20040087795A1 (en) * 2000-07-17 2004-05-06 Borrett Gary Thomas Novel processes for the preparation of 4-phenylpiperidine derivatives
GB0021147D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
GB0021145D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
AU2001211337A1 (en) * 2000-10-06 2002-04-15 Smithkline Beecham Plc Process for the preparation of aryl-piperidine carbinols and intermediates thereof
AU2001210390A1 (en) * 2000-10-20 2002-04-29 Smithkline Beecham Plc Process of the preparation of 3-substituted-4-aryl piperidine compounds
ATE282594T1 (en) * 2001-01-04 2004-12-15 Ferrer Int METHOD FOR PRODUCING (+)-TRANS-4-P-FLUOROPHENYL-3-HYDROXYMETHYL-1-METHYLPIPERIDINE
DE20100529U1 (en) * 2001-01-11 2001-05-10 Synthon Bv Pharmaceutical tablet comprising paroxetine mesylate
US6777554B2 (en) 2001-02-05 2004-08-17 Teva Pharmaceutical Industries Ltd. Preparation of N-methylparoxetine and related intermediate compounds
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
NL1017421C2 (en) * 2001-02-21 2002-01-15 Synthon Bv Process for the production of paroxetine.
EP1362032A2 (en) * 2001-02-24 2003-11-19 Spurcourt Limited Process of preparing paroxetine and intermediates for use therein
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
JP2006512278A (en) * 2001-06-13 2006-04-13 テバ ファーマシューティカル インダストリーズ リミティド Process for producing paroxetine substantially free of alkoxy impurities
WO2003020717A1 (en) * 2001-08-02 2003-03-13 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
EP1434763B1 (en) * 2001-10-12 2018-01-17 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1a antagonists
HUP0401895A2 (en) * 2001-10-22 2004-12-28 Synthon B.V. N-formyl derivatives of paroxetine, process for their preparation and pharmaceutical compositions containing them
EP1465601A4 (en) * 2001-12-28 2006-02-15 Teva Pharma A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
US6956121B2 (en) 2002-03-01 2005-10-18 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates
US7138523B2 (en) * 2002-05-16 2006-11-21 Apotex Pharmachem Inc. Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters
KR100477048B1 (en) * 2002-07-05 2005-03-17 임광민 Piperidine compound, process for the production
BR0314821A (en) * 2002-11-01 2005-08-02 Neurosearch As Piperidine derivative, pharmaceutical composition, use of the piperidine derivative, and, method for treating, preventing or alleviating a disease or disorder or condition of a living animal body
WO2004043921A1 (en) * 2002-11-11 2004-05-27 Natco Pharma Limited Novel process for the preparation of 4-aryl-3-hydroxymethyl-1-methylpiperidines.
JP4901474B2 (en) 2003-05-30 2012-03-21 ランバクシー ラボラトリーズ リミテッド Substituted pyrrole derivatives
BRPI0414343A (en) 2003-09-12 2006-11-07 Pfizer combinations comprising alpha-2-delta ligands and serotonin / norepinephrine reuptake inhibitors
AU2004283196B2 (en) * 2003-09-17 2011-08-25 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
ES2347152T3 (en) * 2003-11-26 2010-10-26 Pfizer Products Inc. DERIVATIVES OF AMINOPIRAZOL AS INHIBITORS OF GSK-3.
CA2548917C (en) 2003-12-11 2014-09-23 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
PE20060437A1 (en) 2004-06-18 2006-06-08 Novartis Ag AZA-BICYCLONONE COMPOUNDS AS CHOLINERGIC LINKS OF nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
JP2008534504A (en) 2005-03-22 2008-08-28 アゼヴァン ファーマスーティカルズ，インコーポレイテッド Β-Lactamyl alkanoic acid for treating premenstrual disorders
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US20060252825A1 (en) * 2005-04-22 2006-11-09 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
AR056980A1 (en) 2005-04-22 2007-11-07 Wyeth Corp DERIVATIVES OF DIHYDROBENZOFURAN, PHARMACEUTICAL COMPOSITIONS, AND USE OF THE SAME
MX2007013021A (en) * 2005-04-22 2008-01-11 Wyeth Corp Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists.
GT200600165A (en) * 2005-04-22 2007-03-14 DIHYDROBENZOFURAN DERIVATIVES AND USES OF THE SAME
US20060264637A1 (en) * 2005-05-16 2006-11-23 Thippannachar Vijayavitthal M Preparation of paroxetine hydrochloride hemihydrate
CA2614289A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
SI1910346T1 (en) 2005-07-19 2019-08-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonist
JP5301991B2 (en) * 2005-07-29 2013-09-25 コンサート ファーマシューティカルズ インコーポレイテッド Novel benzo [d] [1,3] -dioxole derivatives
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
KR101329112B1 (en) 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
EP1948646A2 (en) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
FR2912057B1 (en) * 2007-02-07 2009-04-17 Sanofi Aventis Sa PHARMACEUTICAL COMPOSITION COMPRISING SAREDUTANT AND A SELECTIVE SEROTONIN RECAPTURE INHIBITOR OR SEROTONIN / NOREPINEPHRINE RECAPTURE INHIBITOR
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2644662A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
MX2008014320A (en) 2006-05-09 2009-03-25 Braincells Inc 5 ht receptor mediated neurogenesis.
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
JP2010502722A (en) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド Combinations containing 4-acylaminopyridine derivatives
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008204800A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
JP5489997B2 (en) 2007-07-19 2014-05-14 シマベイ セラピューティクス， インコーポレーテッド N-aza cyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of RUP3 or GPRl 19 receptors for the treatment of diabetes and metabolic diseases
CA2698808A1 (en) * 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2303859A4 (en) * 2008-06-20 2012-08-22 Metabolex Inc Aryl gpr119 agonists and uses thereof
RU2503662C2 (en) 2008-11-14 2014-01-10 Тереванс, Инк. Crystalline form of 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US8778949B2 (en) * 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
ES2543064T3 (en) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compounds of 1- (2-phenoxymethylheteroaryl) piperidine and piperazine
CA2802541A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US9376424B2 (en) 2010-07-01 2016-06-28 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
KR20140045925A (en) 2011-03-17 2014-04-17 루핀 리미티드 Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
CN104039777B (en) 2012-01-31 2016-03-02 卫材R&D管理有限公司 Paroxetine derivatives
US9802925B2 (en) 2014-03-28 2017-10-31 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AU2018333051B2 (en) 2017-09-15 2024-03-21 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
MX2022000709A (en) 2019-07-19 2022-05-19 Bioxcel Therapeutics Inc Non-sedating dexmedetomidine treatment regimens.
WO2023102477A1 (en) * 2021-12-02 2023-06-08 The Johns Hopkins University Peripherally and luminally-restricted inhibitors of the serotonin transporter as treatments for disorders of gastrointestinal motility
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2976291A (en) * 1961-03-21 Ethers of z
US3178438A (en) * 1963-02-06 1965-04-13 Sterling Drug Inc 2-benzyl-3-hydroxy and lower alkoxy piperidines

Also Published As

Publication number Publication date
DK149843B (en) 1986-10-13
US3912743A (en) 1975-10-14
IE38801L (en) 1974-07-30
NO144568B (en) 1981-06-15
JPS58174363A (en) 1983-10-13
JPS5946216B2 (en) 1984-11-10
LU88398I2 (en) 1994-05-04
BE810310A (en) 1974-05-16
JPS49101385A (en) 1974-09-25
NO144568C (en) 1981-09-23
NL7401189A (en) 1974-08-01
NL930003I2 (en) 1994-03-01
FR2215233B1 (en) 1977-01-28
DE2404113A1 (en) 1974-08-08
IE38801B1 (en) 1978-06-07
HK13081A (en) 1981-04-10
CH592059A5 (en) 1977-10-14
SE401827B (en) 1978-05-29
DK149843C (en) 1987-06-15
ES556013A0 (en) 1987-07-16
ES422734A1 (en) 1976-04-01
ES8707224A3 (en) 1987-07-16
FI57932B (en) 1980-07-31
JPS5948826B2 (en) 1984-11-29
FR2215233A1 (en) 1974-08-23
IT1054157B (en) 1981-11-10
FI57932C (en) 1980-11-10
NL179187C (en) 1986-08-01
NO740272L (en) 1974-07-31
US4007196A (en) 1977-02-08
NL179187B (en) 1986-03-03
GB1422263A (en) 1976-01-21
AT333759B (en) 1976-12-10
DE2404113C2 (en) 1985-07-11
LU69264A1 (en) 1974-04-10
CA1038390A (en) 1978-09-12
ATA69674A (en) 1976-04-15

Similar Documents

Publication Publication Date Title
PH10383A (en) 4-phenylpiperidine compounds
JPS514464A (en) Junkatsuyu no saiseihoho
JPS5133102A (en) Sekitan no gasukahoho
JPS511558A (en) Atsushukuhizumi no hikui shirokisanerasutomaa
ZM16774A1 (en) Compounds
JPS5195985A (en) Fukugodenkyokutai no seizoho
AU7031674A (en) Novel compounds
AU6977274A (en) Compounds
ZA74944B (en) Substituted pyrrolidinemethanols
ZA744918B (en) Substituted bebzofurans
KE2889A (en) Pathalocyanine compounds
JPS5152867A (en) yobihyojibanoyobi hizukehyojiban no kudosochi
AU7040074A (en) Compounds
IL45321A0 (en) Substituted phenylglycylcephalosporins
JPS5137457A (en) Sokohoisuto no itsusoboshisochi
JPS5110895A (en) Horikaaboneeto no seizohoho
ZA744584B (en) Novel n-hydroxy-amidine compounds
JPS517064A (en) Goseimeiboku no seizohoho
JPS5129210A (en) Mushukaninnikumatsu no seizoho
ZA747405B (en) Substituted acetamidocephalosporins
JPS511508A (en) Kazangarasunyoru tainetsushogekiseitojiki no seizoho
AU6436474A (en) Compounds
AU6677774A (en) Triphenyl-tin compounds
AU7528074A (en) Compounds
GB1408729A (en) Sulphilimine compounds